Dopaminergic medication boosts action-effect binding in Parkinson's disease

Area of Science:

• Neuroscience
• Cognitive Psychology
• Movement Disorders

Background:

• Parkinson's disease (PD) impairs motor control, but its effect on the subjective experience of voluntary action is unclear.
• The sense of agency (SoA) involves feeling in control of actions and their outcomes.
• Action-effect binding, a temporal perception of actions and their consequences, serves as an indirect measure of SoA.

Purpose of the Study:

• To investigate how Parkinson's disease and dopaminergic medication affect the sense of agency.
• To examine the relationship between dopamine availability and action-effect binding in PD patients.

Main Methods:

• Nine Parkinson's disease patients and age-matched controls performed temporal judgment tasks involving voluntary actions and auditory effects.
• Participants were tested both on and off dopaminergic medication.
• Action-effect binding was measured by assessing the perceived timing of actions and their subsequent effects.

Main Results:

• PD patients off medication showed action-effect binding comparable to controls.
• PD patients on dopaminergic medication exhibited significantly increased action-effect binding compared to their off-medication state.
• This suggests dopamine enhances the temporal association between actions and their effects.

Conclusions:

• Dopamine plays a crucial role in the subjective experience of instrumental action and sense of agency.
• Altered action-effect binding in medicated PD patients may relate to impulse control disorders and psychosis.
• The study provides insights into dopamine's contribution to action experience in Parkinson's disease.